Czech biotechnology company, SOTIO, recently started preclinical development of its first two bispecific antibody drug conjugates (ADCs), which it says are “just the beginning” of what it has in store for its next-generation ADC pipeline. DDW’s Megan Thomas speaks with SOTIO’s Chief Scientific Officer, Martin Steegmaier, about the company’s pipeline. Read More
SOTIO Biotech has presented preclinical data on two of its leading antibody-drug conjugate (ADC) candidates, SOT109 and SOT106, demonstrating strong anti-tumour activity and favourable tolerability profiles across multiple tumour models. The data shared at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL supports… Read More
New data supporting SOT201, a PD-1-targeting immunocytokine, in advanced solid tumours was presented at the 2024 Society for Immunotherapy of Cancer (SITC) Meeting in Houston, TX, US. SOT201 is a PD-1-targeted and cis-acting attenuated IL-15 agonist designed to preferentially activate PD-1+CD8+ T cells, inducing superior anti-tumour… Read More
